RT Journal Article SR Electronic T1 Vinorelbine and Cisplatin in Patients with Advanced Non-small Cell Lung Cancer with Interstitial Pneumonia JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 1697 OP 1701 VO 35 IS 3 A1 NAOHIRO WATANABE A1 SEIJI NIHO A1 KEISUKE KIRITA A1 SHIGEKI UMEMURA A1 SHINGO MATSUMOTO A1 KIYOTAKA YOH A1 HIRONOBU OHMATSU A1 KOICHI GOTO YR 2015 UL http://ar.iiarjournals.org/content/35/3/1697.abstract AB Aim: The aim of the present study was to investigate the efficacy and tolerability of vinorelbine and cisplatin for the treatment of patients with advanced (stage IIIB, IV or relapse) non-small cell lung cancer (NSCLC) with interstitial pneumonia (IP). Patients and Methods: A total of 67 patients treated with vinorelbine and cisplatin as a first-line chemo therapy between January 2002 and December 2013 were retrospectively reviewed. Results: The overall response rate was 34.3% [95% confidence interval (CI)=22.9%-45.7%). The median progression-free survival, median overall survival, and 1-year survival rates were 3.7 months (95% CI=3.1-4.3 months), 7.4 months (95% CI=5.4-9.4 months), and 22.4% (95% CI=12.4%-32.4%), respectively. The incidence of acute exacerbation of IP following first-line chemotherapy was 10.4%. Conclusion: The combination of vinorelbine and cisplatin is a feasible treatment option for advanced NSCLC patients with IP, after careful consideration of the potential risks and benefits on an individual basis.